Skip to main content

Carlos Manuel de Castro III

Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Box 3961 Med Ctr, Durham, NC 27710
Box 3961, 2400 Pratt St North Pavilion Suite 5000, Durham, NC 27710

Overview


Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas

Current Appointments & Affiliations


Professor of Medicine · 2021 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Member of the Duke Cancer Institute · 1988 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Journal Article Blood Adv · April 22, 2025 Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with paroxysmal nocturn ... Full text Link to item Cite

Modified Delphi panel consensus recommendations for management of severe aplastic anemia.

Journal Article Blood Adv · August 13, 2024 Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Del ... Full text Link to item Cite

Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.

Journal Article Blood Adv · June 11, 2024 Patients with paroxysmal nocturnal hemoglobinuria (PNH) experience complement-mediated intravascular hemolysis leading to anemia, fatigue, and potentially life-threatening thrombotic complications. Pegcetacoplan, a C3 inhibitor, demonstrated sustained impr ... Full text Link to item Cite
View All Publications

Recent Grants


External Quality Assurance Program Oversight Laboratory (EQAPOL)

ResearchInvestigator · Awarded by National Institutes of Health · 2024 - 2031

Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2026

CLNP023C12303

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2026

View All Grants

Education, Training & Certifications


University of Texas, Dallas · 1985 M.D.